CD274 and non-small cell lung carcinoma: Contrary to the majority of pharmacoeconomic assessments, the pivotal result of this review revealed that a distinct subset of studies failed to demonstrate the cost-effectiveness of PD-L1 testing and pembrolizumab for the first-line treatment of non-small cell lung cancer (NSCLC).